返回成功案例
医疗健康

Laboratorios Saval S.A. has acquired a pharmeceutical processing plant

Laboratorios Saval S.A. has acquired a pharmeceutical processing plant in Costa Rica from Laboratorios Stein S.A.

Laboratorios Saval is a Chilean company with more than 80 years of history. It began its history in Spain in the 1930s and today, has a presence in more than 14 countries. The company manufactures and distributes pharmaceuticals in the areas of infectious diseases, ophthalmology, immunology and oncology, gastroenterology, bronchopulmonary, cardiology, psychiatry and rheumatology.

Laboratorios Stein is a leading company in Latin America in the commercialization and distribution of highly complex pharmaceutical products including innovative products, biosimilars and complex generics.

Oaklins’ team in Chile acted as financial advisor to Laboratorios Saval in this transaction.

我们的服务
交易方

联系交易团队

Felipe Porzio

管理合伙人
圣地亚哥, 智利
Oaklins LarrainVial

Agustin Achondo

总监
圣地亚哥, 智利
Oaklins LarrainVial

Alberto Parot

分析员
圣地亚哥, 智利
Oaklins LarrainVial

相关交易

Leika Medical Equipments Ltd. has been acquired by Angus Capital
私募基金 | 医疗健康

Leika Medical Equipments Ltd. has been acquired by Angus Capital

The shareholders of Leika Medical Equipments Ltd. have sold the company to Angus Capital.

更多信息
Phen’X Technologies has sold a majority stake to Ciclad
私募基金 | 医疗健康 | 工业机械与零部件

Phen’X Technologies has sold a majority stake to Ciclad

The shareholders of Phen’X Technologies have completed a primary majority LBO with private equity fund Ciclad.

更多信息
Medis Medical Imaging and GE HealthCare announce collaboration focused on non-invasive coronary assessments
医疗健康 | 科技、媒体及通讯

Medis Medical Imaging and GE HealthCare announce collaboration focused on non-invasive coronary assessments

Medis Medical Imaging Systems B.V., a leading cardiac imaging software company, have completed a strategic investment to further develop its revolutionary non-invasive cardiovascular imaging solution. The company has announced its collaboration with GE HealthCare (Nasdaq: GEHC), a global leader in medical technology, pharmaceutical diagnostics and innovation in digital solutions, to contribute to the advancement of precision care in the diagnosis and treatment of coronary artery disease (CAD).

更多信息